Management

Dr Wolgen leads the executive management team who in turn direct their respective teams in the conduct of the business of Group. The executives meet regularly and collaborate on key initiatives to ensure progress is made to achieve annual and longer term objectives.

Malcolm Bull

Head of Australian Operations and Investor Relations, Joined 2019
BEc (Hons, University of Adelaide)
MEc (Monash University)

Mr Malcolm Bull joined CLINUVEL in January 2019 and initially built out the Company’s investor relations program with a focus on analyst and Australian institutional engagement. Recognising the need for greater operational support in Australia amidst the COVID-19 pandemic, Mr Bull’s role with CLINUVEL evolved in 2021 to the remit of Head of Australian Operations and Investor Relations. Previously an economist within the Australian Federal Government and private sector, Mr Bull then spent more than two decades in banking across credit, business development and strategy, and relationship management, working with Commonwealth Bank of Australia, Bank of Western Australia, National Australia Bank, and ANZ. This included time in general management for ANZ in the Philippines and as part of the Victorian state management team for CBA Corporate. Mr Bull has managed to attract seven sell-side analysts since his arrival and increased institutional ownership of CLINUVEL from 25% to 35% of issued capital.

Antonella Colucci

VP, Commercial Affairs, Joined 2011
MA (European Studies and Global Affairs, Catholic University of the Sacred Heart)
MA (Modern Languages, IULM Milan)
Executive education: Harvard Business School, London Business School

Mrs Antonella Colucci is responsible for commercial matters ex-North America while working closely with the U.S. team to ensure continuity of business. Having spent many years working within the medical industry in Italy, Mrs Colucci was instrumental in the expansion of CLINUVEL’s Italian 648/96 program and subsequent Swiss special access scheme. These two programs – which facilitated subsidised reimbursement of the drug prior to its marketing authorisation – provided CLINUVEL with commercial proof-of-concept for SCENESSE® and laid the foundations for Mrs Colucci to lead the Company’s successful commercial activities since 2016. With responsibilities across pricing, compliance, and distribution, Mrs Colucci is currently focused on expanding the Company’s commercial reach in both new and existing regions.

Dr Azza Hamila

Head of Quality Assurance and Drug Safety, Joined 2015
BPharm (University Claude Bernard)
MPharm (University Paris Descartes)

Dr Azza Hamila has played a central role in CLINUVEL’s commercial scale-up, establishing new internal standards in GxP, with a focus on manufacturing, distribution, and pharmacovigilance. Her work has enabled the Company to achieve long-standing compliance, giving authorities comfort that CLINUVEL conforms to strict international regulations and can maintain the licences necessary to perform critical manufacturing and distribution functions in-house. Dr Hamila’s position encompasses both Responsible Person and Qualified Person roles in various jurisdictions within the quality management system, as well as being responsible for supplier management and patient safety. She has previously held quality assurance roles with Orphan Europe (Recordati), Sanofi Aventis, and Roche before joining CLINUVEL in 2015.

Lachlan Hay

Director of Global Operations, Joined 2007
BA (Media Comms, University of Melbourne)
MA (International Relations, Freie Universität Berlin)
Executive education: INSEAD, Harvard Business School, NYU Stern, London Business School

Mr Lachlan Hay supports the executive and senior management teams as well as maintains responsibility for the delivery of key business objectives. Having joined the business in a corporate communications role in Australia, Mr Hay then assumed roles in Europe and Asia. He was the first General Manager of the UK business, overseeing the introduction of SCENESSE® into European markets since 2016, and assumed a broader operational position in 2021 in response to the needs of the business. On 1 July 2024, Mr Hay assumed the position of Chief Operations Officer, providing him more responsibilities. He is also completing his law degree (LLM).

Dr Emilie Rodenburger

Director, Global Clinical Affairs
Joined April 2024
PharmD (Paris Descartes University, France)
MSc (Paris-Sud University, France)

Dr Emilie Rodenburger rejoined CLINUVEL in April 2024 as Director, Global Clinical Affairs. Returning to CLINUVEL after four years with Roche in senior clinical roles, Dr Rodenburger oversees CLINUVEL's global clinical program, evaluating melanocortin based drugs for a range of disorders of the skin and brain. Her immediate focus will be to ensure full enrolment and analyses of the CUV105 study of SCENESSE® in vitiligo (loss of pigmentation). A pharmacist (PharmD) with a master's degree in cancer biology, Dr Rodenburger previously worked with the CLINUVEL Group for over a decade in clinical development roles in Australia, the USA and Europe. During this time, she led the Company's first vitiligo trials as well as being one of two clinical managers completing the EPP program resulting in the successful approval and commercialisation of SCENESSE® as the first systemic photoprotective therapy.

Dr David Soloman

Head of Regulatory Affairs, Joined April 2025
BPharm Hons MRPharmS (King’s College London, University of London)
Diploma in Clinical Science (Dip Clin Sci, University of Wales)

Dr Solomon joined CLINUVEL with over 35 years of experience in the pharmaceutical industry. As a pharmacist, he has worked across medical affairs, pharmacovigilance, clinical research and regulatory affairs. Prior to joining CLINUVEL, he worked in both large companies, such as GSK, Roche, Eisai, and UCB, and small biotech start-ups such as GW Pharmaceuticals, EUSA Pharma, and Zogenix. Dr Solomon has led Global Regulatory Affairs Departments, building teams of regulatory professionals in the EU, UK, and U.S.A.. He has experience in orphan disease areas, developing a wide variety of regulatory strategies, across all stages of drug development. Dr Solomon has successfully led teams in the submission and approval of many regulatory filings, including Marketing Authorisation Applications, New Drug Applications, paediatric investigational drugs, fast track applications, and numerous Clinical Trial/Investigational New Drug applications.

Dr Linda Teng

Director of North American Operations, Joined 2007
BPharm (National Taiwan University)
Doctor of Health Administration (Medical University of South Carolina)

As Director of North American Operations, Dr Linda Teng has established the Company’s commercial presence, building a network of Specialty Centers and commercial programs enabling EPP patients to receive treatment in both the U.S.A. and Canada. With a background in clinical pharmacy and clinical pharmaceutical development – at BioMarin and for more than 16 years at CLINUVEL – Dr Teng also heads the vitiligo program in North America. The U.S. team has grown quickly over the past 18 months to incorporate new functions, including patient support and in-house counsel, adding complexity but greater bandwidth to the operations under Dr Teng’s purview.

Peter Vaughan

Chief Financial Officer, Joined April 2024
BBus (Acc) (Swinburne University)
Snr. Exec. MBA (Melbourne University)
Member, Institute of Chartered Accountants ANZ
GAICD, AGIA
Cert. Climate Change: Financial Risks and Opportunities (Imperial College, London)

Mr Peter Vaughan joined CLINUVEL in April 2024 and assumed the Chief Financial Officer role on 1 July 2024. Mr Vaughan has over 20 years of experience in listed and unlisted companies in Australia, the U.S.A., Europe, and Asia. Most recently with Toys “R” Us ANZ Limited as a strategic financial advisor, he has previously held CFO and Company Secretary roles at Titomic (ASX:TTT), Immuron (ASX:IMC, NASDAQ:IMRN), Amaero (ASX:A3D) and Respiri (ASX:RSH), among others. He has led capital raisings, M&A and licensing deals within life science companies, as well as the dual listing of two Australian companies on the Nasdaq (Immuron Limited and Prima Biomed Limited (now Immutep)). Mr Vaughan is a Chartered Accountant, with a BBus (Accounting) from the Swinburne University of Technology and a Senior Executive MBA from Melbourne Business School. He is also a member of Australian Institute of Company Directors and Governance Institute of Australia.

Dr Dennis Wright

Chief Scientific Officer, Joined 2005
BPharm (University of Sydney)
MSc (University of Sydney)
PhD (University of Sydney)
GradCert Health Economics (Monash University)

Dr Dennis Wright has been at the core of the Company’s clinical program and regulatory affairs for nearly two decades in the role of Chief Scientific Officer. A pharmacist with a PhD in xenobiotic metabolism, Dr Wright has a pharmaceutical career spanning more than 40 years with Nicholas Kiwi, Faulding/Mayne, CSL and CLINUVEL. During this time, he worked across basic and clinical research, regulatory affairs, pharmacovigilance, business development, in-licensing, and marketing. It is from this diverse background that he has led CLINUVEL’s late-stage clinical development program for EPP as well as steering successful regulatory filings for SCENESSE® in Europe, the U.S.A., Australia, and Israel. His role has extended in recent years to facilitate new clinical programs for afamelanotide as well as overseeing new product development and scientific affairs.